Trial Profile

A phase 2 clinical trial to evaluate the effect of lemzoparlimab in combination with Keytruda in advanced solid tumors

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 24 May 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lemzoparlimab (Primary) ; Pembrolizumab (Primary) ; Toripalimab (Primary)
Indications Solid tumours
Focus Therapeutic Use
Sponsors I-MAB Biopharma

Most Recent Events

18 May 2021 Status changed from planning to recruiting, according to an I-MAB Biopharma Media release.
18 May 2021 According to an I-MAB Biopharma Media release, patient enrollment in this study will be completed by Q4 2021 with the preliminary topline data expected thereafter.
21 Sep 2020 Results published in the Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com